pillbase.ru

KADCYLA

Active substance: ado-trastuzumab emtansine

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · TRASTUZUMAB EMTANSINE 20 mg/mL

United StatesActive

Marketing holder: Genentech, Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Кадсила®
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 160 мг, 160 мг (original in Russian, GRLS)
    ЛП-№(000832)-(РГ-RU)
    Ф.Хоффманн-Ля Рош Лтд
  • Кадсила®
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 100 мг, 100 мг (original in Russian, GRLS)
    ЛП-002692
    Ф. Хоффманн-Ля Рош Лтд.
EU 1
  • Kadcyla
    trastuzumab emtansine
    EMEA/H/C/002389
    Roche Registration GmbH
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-3967-7a54-85e3-179c4c60f586,01a120c5-108b-7e6d-9449-d1462535445f;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a12091-b65e-7548-8e63-7955b57a6527,01a12096-00b1-78e7-af6d-3c37abbee332;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
50242-087
Registration status
Active
Dispensing
Prescription only
Route
INTRAVENOUS
Sources
  • product · openFDA NDC · 50242-087 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 50242-087 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 50242-087 · Verified 2026-10-09 · open in source